Creatine Treatment in Psychiatric Disorders
Creatine as a New Treatment for Schizophrenia:A Double-Blind Trial
Creatine as a New Treatment for Schizophrenia:A Double-Blind Trial
Sponsor study identifier
interventional
12
1 country
1
Study Start
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2006
Actual (reported)Study Completion
March 2006
Actual (reported)Creatine plays a pivotal role in brain energy homeostasis. Creatine supplementation is widely used in enhancing sports performance, and has been tried in the treatment of neurological, neuromuscular and atherosclerotic disease with a paucity of side effects. Dechent et al (1999) studied the effect of oral creatine supplementation for 4 wk demonstrating a statistically significant increase of mean concentration of total creatine across brain regions. These findings suggest the possibility of using oral creatine supplementation to modify brain high-energy phosphate metabolism in subjects with various brain disorders, including schizophrenia and major depression. Recently, Rae et al (2003) reported that creatine supplementation for 6 weeks had a significant positive effect on both working memory and Raven matrices. Several independent lines of evidence suggest the possible involvement of altered cerebral energy metabolism in schizophrenia. We are performing a double blind cross-over study of creatine in schizophrenia. Forty patients will be treated with creatine for 3 months in a double-blind crossover design. Rating scales will include scales for assessing negative and positive symptoms of schizophrenia, clinical global impressions scale, scales for side-effects and a cognitive battery Creatine effects on brain energy metabolism and its possible cognitive enhancing properties raise the possibility of developing a new therapeutic strategy in schizophrenia focusing on treating metabolic hypoactive brain areas including frontal regions.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
August 31, 2005
Actual (reported)September 1, 2005
Actual (reported)March 2006
Actual (reported)March 2006
Actual (reported)Positive and Negative Syndrome Scale
Clincal Global Impression
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Beersheva Mental Health Center
Beersheva, Israel
Kaptsan A, Odessky A, Osher Y, Levine J. Lack of efficacy of 5 grams daily of creatine in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007 Jun;68(6):881-4. doi: 10.4088/jcp.v68n0609.
RH Belmaker, MD
Ben Gurion University of the Negev + Beersheva Mental Health Center
12 participants (actual enrollment reported by the registry).
First Submitted
August 31, 2005
First Posted
September 1, 2005
Study Start
September 2004
Date type not reportedThis date has not been verified as actual or estimated.
L-Theanine in the Management of Schizophrenia
Contact the study team to confirm eligibility.
Primary Completion
March 2006
Actual (reported)Study Completion
March 2006
Actual (reported)Last Updated
July 29, 2009
Record last verified: 2005-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: